CLINICAL TRIALS PROFILE FOR TALAMPANEL
✉ Email this page to a colleague
Clinical Trials for Talampanel
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00034814 ↗ | Multicenter Trial for Adults With Partial Seizures | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients. |
| NCT00034814 ↗ | Multicenter Trial for Adults With Partial Seizures | Completed | Teva Pharmaceutical Industries | Phase 2 | To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients. |
| NCT00036296 ↗ | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1/Phase 2 | The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's disease. It is not clear why people with Parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors. |
| NCT00036296 ↗ | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Completed | Teva Pharmaceutical Industries | Phase 1/Phase 2 | The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's disease. It is not clear why people with Parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors. |
| NCT00057460 ↗ | Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | This study will use transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to test the safety of an experimental anti-epileptic drug called Talampanel and learn how it affects brain activity. Talampanel blocks a type of brain receptor called AMPA; inhibiting this receptor may result in anti-seizure activity. TMS stimulates the outer part of the brain, called the cortex. For this procedure, an insulated wire coil is placed on the subject's scalp. A brief electrical current is passed through the coil, creating a magnetic pulse that stimulates the brain. This may cause a pulling sensation on the skin under the coil and muscle twitching in the face, arm, or leg. EEG records the electrical activity of the brain, in the form of brain waves. For this procedure, electrodes (metal discs with a conductive gel) attached to wires are affixed to the scalp with a paste and the brain activity is recorded. Healthy normal volunteers between 18 and 45 years of age may participate in this study. Candidates will be screened with a physical and neurological examination, electrocardiogram (EKG), blood tests, and blood pressure measurement. Women who are pregnant or nursing are excluded from the study. Participants will come to the NIH Clinical Center for three testing sessions, at least 1 week apart, and a final follow-up visit. The procedure for each test session is as follows: 7 AM - Blood pressure is measured, EKG and EEC leads are placed, a heparin lock is inserted, and a blood sample is drawn. The heparin lock is a thin needle enclosed in a thin plastic tube. The needle guides the tube into a vein and is then removed, leaving the tube in place. The indwelling tube allows multiple blood samples to be drawn without repeated needle sticks. 8 - 9 AM - TMS followed by EEG recording. 9 AM - Administration of Talampanel or placebo (pill with no active ingredient) by mouth. 10 AM - Blood sample #2. 10 AM -11 AM - TMS, followed by EEG recording every 5 minutes. 11 AM - Blood sample #3. 12 PM - Blood sample #4. 11 AM - 1 PM - EEG recording every 5 minutes/ 4 PM - Blood sample #5. 5 PM - Discharge from Clinical Center. At the final follow-up visit, the participant will talk with the doctor and have one final blood draw. |
| NCT00062504 ↗ | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Terminated | National Cancer Institute (NCI) | Phase 2 | To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas. |
| NCT00062504 ↗ | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Talampanel
Condition Name
Clinical Trial Locations for Talampanel
Trials by Country
Clinical Trial Progress for Talampanel
Clinical Trial Phase
Clinical Trial Sponsors for Talampanel
Sponsor Name
